CIK 0001815442
- Large accelerated filer
Kymera Therapeutics, Inc.
Sign in to watch- Ticker
- KYMR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 812992166
- Phone
- +1 857-285-5314
- Business address
- 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
- Former names
- Kymera Therapeutics, Inc.
- 4 Derivatives Options or other derivatives
- 4 Planned sale Director sold 4,500 shares at $50.00 ($225,000)
- 4 Planned sale Director sold 5,000 shares at $49.04 ($245,186)
- 4 Planned sale Director sold 12,000 shares at an average $46.10 ($553,200)
- 4 Planned sale Chief Executive Officer sold 30,000 shares at $49.00 ($1,470,000)
- 4 Planned sale Director sold 6,349 shares at $49.00 ($311,101)
- 4 Open-market sale Chief Operating Officer sold 2,575 shares at $29.30 ($75,436)
- 4 Grant or award Chief Business Officer acquired 50,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Exercise or conversion Chief Financial Officer acquired 25,000 shares (option exercise)
- 4 Open-market sale Chief Legal Officer sold 2,241 shares at an average $30.45 ($68,239)
- 4 Open-market sale Chief Operating Officer sold 1,383 shares at an average $30.45 ($42,113)
- 4 Open-market sale Chief Financial Officer sold 7,035 shares at an average $30.45 ($214,219)
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Medical Officer sold 5,740 shares at an average $30.45 ($174,786)
- 4 Exercise or conversion Chief Executive Officer acquired 10,000 shares (option exercise)
- 4 Exercise or conversion Chief Financial Officer acquired 10,000 shares (option exercise)
- 4 Open-market sale Chief Legal Officer sold 3,129 shares at $41.75 ($130,645)
- 4 Planned sale Director sold 2,500 shares at $49.00 ($122,500)
- 4 Planned sale Director sold 13,500 shares at an average $48.28 ($651,766)
Page 5 of 15 · 296 filings